Studi In Silico Turunan Imidazopirimidin sebagai Agen Antikanker Payudara terhadap Protein ER-α, ADMET, dan Drug-Likeness In Silico Study of Imidazopyrimidine Derivatives as Breast Anticancer Agents against ER-α Protein, ADMET, and Drug-Likeness
Article Sidebar
Page Numbers:
1754-1773
Digital Object Identifier:
10.58578/masaliq.v6i4.10974
Viewed: 0 times
Downloaded: 0 times
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:
Muhammad Chandra1*, Fajriah Azra2 
Copyright :
Authors retain copyright and grant the journal right of first publication.
Main Article Content
Abstract
Breast cancer is one of the leading causes of global mortality, requiring the development of new therapeutic agents that are more effective and selective. This study aims to evaluate the potential of 20 imidazopyrimidine derivative compounds as candidate selective inhibitors of Estrogen Receptor Alpha (ER-α). This study used an in silico approach that included molecular docking using MOE 2019.0102 software with ER-α target protein (PDB ID: 3ERT), followed by drug-likeness screening based on Lipinski’s Rule of Five and prediction of the ADMET pharmacokinetic profile through the SwissADME and pKCSM web servers. The molecular docking results showed that Compound 15 had the strongest binding affinity, with a docking score (S) of -11.94 kcal/mol and a Root Mean Square Deviation (RMSD) value of 0.7 Å, better than the control ligand 4-hydroxytamoxifen (S = -11.1 kcal/mol; RMSD = 1.8 Å). Other potential compounds that showed high affinity were Compound 13 (S = -11.20 kcal/mol) and Compound 1 (S = -10.88 kcal/mol). The ligand-protein complex was stabilized by hydrogen bonds, hydrophobic interactions, and pi-sulfur interactions in the receptor’s active pocket. Physicochemical prediction showed that most compounds met Lipinski’s Rule of Five criteria for oral drug candidates and had good ADMET solubility, permeability, and elimination profiles without indications of hepatotoxicity. The conclusion of this study affirms that imidazopyrimidine derivatives, particularly Compounds 15, 13, and 1, have potential as candidate ER-α-targeted breast anticancer agents. These findings provide an initial contribution to the development of breast anticancer therapy candidates and need to be followed up through experimental in vitro and in vivo studies.
Downloads
Article Details
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
References
Ahmad, S., Qazi, S., Bano, N., Uddin, R., Gautam, P. K., & Raza, K. (2026). Multitarget docking and molecular enumeration reveal DdpMPyPEPhU as a potent modulator of cell cycle, glucocorticoid, and estrogen signalling in breast cancer. PLOS ONE, 21(3), Article e0344028. https://doi.org/10.1371/journal.pone.0344028
Azis, F. D. A., Shofia, V., Latifah, L., & Purnomo, H. (2026). Molecular docking of kaempferol, quercetin, and vitamin C from shallot bulb as antioxidant agents targeting peroxiredoxin 5 for the protection of mitochondrial DNA against oxidative stress. Medical Sains: Jurnal Ilmiah Kefarmasian, 11(1), 51–58. https://doi.org/10.37874/ms.v11i1.1836
Boudou, F., Belakredar, A., Berkane, A., Keziz, A., Alsaeedi, H., Cornu, D., Bechelany, M., & Barhoum, A. (2024). Phytochemical profiling and in silico evaluation of Artemisia absinthium compounds targeting Leishmania N-myristoyltransferase: Molecular docking, drug-likeness, and toxicity analyses. Frontiers in Chemistry, 12, Article 1508603. https://doi.org/10.3389/fchem.2024.1508603
Bugnon, M., Röhrig, U. F., Goullieux, M., Perez, M. A. S., Daina, A., Michielin, O., & Zoete, V. (2024). SwissDock 2024: Major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic Acids Research, 52(W1), W324–W332. https://doi.org/10.1093/nar/gkae300
Chen, Y., Feng, Y., Luan, W., Zhang, W., & Di, L. (2025). Discovery of PKM2 activators from Aconiti Lateralis Radix Praeparata via computer-aided drug design and experimental validation. Fitoterapia, 186, Article 106793. https://doi.org/10.1016/j.fitote.2025.106793
Dahiya, M., & Dureja, H. (2022). Sorafenib for hepatocellular carcinoma: Potential molecular targets and resistance mechanisms. Journal of Chemotherapy, 34(5), 286–301. https://doi.org/10.1080/1120009X.2021.1955202
Dai, R., Bao, X., Zhang, Y., Huang, Y., Zhu, H., Yang, K., Wang, B., Wen, H., Li, W., & Liu, J. (2023). Hot-spot residue-based virtual screening of novel selective estrogen-receptor degraders for breast cancer treatment. Journal of Chemical Information and Modeling, 63(23), 7588–7602. https://doi.org/10.1021/acs.jcim.3c01503
Hasanova, S., Gumus, E., & Zor, E. (2026). Recent advances in electrochemical sensors for the detection of anticancer drugs. Journal of Pharmaceutical and Biomedical Analysis, 270, Article 117278. https://doi.org/10.1016/j.jpba.2025.117278
Kaur, K., Verma, H., Gangwar, P., Jangid, K., Dhiman, M., Kumar, V., & Jaitak, V. (2024). Design, synthesis, in silico and biological evaluation of new indole based oxadiazole derivatives targeting estrogen receptor alpha. Bioorganic Chemistry, 147, Article 107341. https://doi.org/10.1016/j.bioorg.2024.107341
Mahal, A., Al-Janabi, M., Eyüpoğlu, V., Alkhouri, A., Chtita, S., Kadhim, M. M., Obaidullah, A. J., Alotaibi, J. M., Wei, X., & Pratama, M. R. F. (2024). Molecular docking, drug-likeness and DFT study of some modified tetrahydrocurcumins as potential anticancer agents. Saudi Pharmaceutical Journal, 32(1), Article 101889. https://doi.org/10.1016/j.jsps.2023.101889
Mahammad, S. P., Muripiti, V., Narsaiah, C., Rameshwar, N., & Mavurapu, S. (2026). Synthesis of thiazolidine-2,4-dione tethered pyrazolyl coumarin hybrids and in-silico ADMET predictions. Chemical Data Collections, 63, Article 101237. https://doi.org/10.1016/j.cdc.2026.101237
Manda, S., Sahoo, B. K., Chatakonda, V., Padmaja, P., Akula, R. K., Abhale, A. K., Pasikanti, S., Ramesh, M., & Reddy, P. N. (2026). Paullones and structurally modified pyrrolo[1,2-a]quinoxalin-4(5H)-ones as anticancer scaffolds: Design, synthesis, molecular modelling, ADMET and biological evaluation. Journal of Molecular Structure, 1368, Article 146224. https://doi.org/10.1016/j.molstruc.2026.146224
Marino, P., Mininni, M., Deiana, G., Marino, G., Divella, R., Bochicchio, I., Giuliano, A., Lapadula, S., Lettini, A. R., & Sanseverino, F. (2024). Healthy lifestyle and cancer risk: Modifiable risk factors to prevent cancer. Nutrients, 16(6), Article 800. https://doi.org/10.3390/nu16060800
Marisa, D., Hayatie, L., Juliati, S., Suhartono, E., & Komari, N. (2021). Molecular docking of phytosterols in Stenochlaena palustris as anti-breast cancer. Acta Biochimica Indonesiana, 4(2), 59. https://doi.org/10.32889/actabioina.59
Márquez-Mendoza, J. M., Baranda-Ávila, N., Lizano, M., & Langley, E. (2025). Micro-RNAs targeting the estrogen receptor alpha involved in endocrine therapy resistance in breast cancer. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1871(5), Article 167783. https://doi.org/10.1016/j.bbadis.2025.167783
Masand, V. H., Al-Hussain, S. A., Alzahrani, A. Y., Al-Mutairi, A. A., Hussien, R. A., Samad, A., & Zaki, M. E. A. (2024). Estrogen receptor alpha binders for hormone-dependent forms of breast cancer: e-QSAR and molecular docking supported by X-ray resolved structures. ACS Omega, 9(14), 16759–16774. https://doi.org/10.1021/acsomega.4c00906
Narasimhan, B., & Sapra, A. (2026). Benzimidazole derivatives as anticancer agents: A review of recent literature and structure-activity relationships. Letters in Drug Design & Discovery, Article 100237. https://doi.org/10.1016/j.lddd.2025.100237
Patel, S., Globisch, C., Pulugu, P., Kumar, P., Jain, A., & Shard, A. (2022). Novel imidazopyrimidines-based molecules induce tetramerization of tumor pyruvate kinase M2 and exhibit potent antiproliferative profile. European Journal of Pharmaceutical Sciences, 170, Article 106112. https://doi.org/10.1016/j.ejps.2021.106112
Patel, S., Pulugu, P., Das, R., Chowdhury, M. G., Chatterjee, D. R., Srivastava, A., & Shard, A. (2025). Comprehensive exploration of novel imidazopyrimidine derivatives: Design, synthesis, computational assessment, and anti-breast cancer activity. Journal of Molecular Structure, 1326, Article 141062. https://doi.org/10.1016/j.molstruc.2024.141062
Poli, G., Martinelli, A., & Tuccinardi, T. (2016). Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(Suppl. 2), 167–173. https://doi.org/10.1080/14756366.2016.1193736
Porras, L., Ismail, H., & Mader, S. (2021). Positive regulation of estrogen receptor alpha in breast tumorigenesis. Cells, 10(11), Article 2966. https://doi.org/10.3390/cells10112966
Ramírez, D., & Caballero, J. (2018). Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules, 23(5), Article 1038. https://doi.org/10.3390/molecules23051038
Shahab, M., Zulfat, M., & Zheng, G. (2024). Structure-based virtual screening, molecular simulation and free energy calculations of traditional Chinese medicine, ZINC database revealed potent inhibitors of estrogen-receptor α (ERα). Journal of Biomolecular Structure and Dynamics, 42(23), 13261–13274. https://doi.org/10.1080/07391102.2023.2275174
Varela-Rial, A., Majewski, M., & De Fabritiis, G. (2022). Structure based virtual screening: Fast and slow. WIREs Computational Molecular Science, 12(2), Article e1544. https://doi.org/10.1002/wcms.1544
Wu, J., Li, P., Mu, Y., Peng, R., Zhao, Z., Lei, J., Tu, A., Gao, Z., Bai, Y., & Wu, G. (2024). Structural optimization of quinazolin-4-one derivatives as novel SARS-CoV-2 Mpro inhibitors by molecular simulation. Letters in Drug Design & Discovery, 21(17), 3983–3997. https://doi.org/10.2174/0115701808330125240812104856
Zaman, S. R., Parvin, M. S., Akter, M., Fuad, K. M., Islam, S. R., Mondol, M., & Islam, M. E. (2026). Computational identification of natural inhibitors of human neutrophil elastase as potential therapeutics for chronic obstructive pulmonary disease. Immunobiology, 231(4), Article 153209. https://doi.org/10.1016/j.imbio.2026.153209